Aclaris Therapeutics, Inc. ACRS
Set alert
3.80 USD -0.17 -4.28%
At close
3.99 +0.19 +5.00%
Pre-market · Nov 3, 7:20 AM ET
3.77 Day range 4.04
2.10 52-week range 6.60
- YTD
- +26.25%
- 1 year
- +48.44%
- Open
- 4.09
- Prev close
- 3.97
- Mkt cap
- 588.94M
- Vol
- 1.64M
- Avg vol
- 2.91M
- EPS
- -0.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.77
- High
- 4.04
- Forward P/E
- -5.00
- Beta
- 0.12
- Short ratio
- 0.47
- Inst. own
- 90.21%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.70
- 200-d avg
- 1.58
- 1y target
- 10.00
Analyst view
Consensus: buy
Buy
Price target (mean) 10.00 +163.2% upside
Now 3.80
- Target (low)
- 5.00
- Target (mean)
- 10.00
- Target (high)
- 20.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy2
- Buy3
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.324 | -0.54 – -0.10 | -0.02 | -1520.0% | 6.25M | -64.4% | 5 |
| Next quarter | -0.21 | -0.21 – -0.21 | -0.24 | +12.5% | 2.58M | +7.7% | 1 |
| Current year | -0.864 | -1.13 – -0.58 | -1.27 | +32.0% | 15.75M | -49.6% | 5 |
| Next year | -0.52 | -0.59 – -0.45 | -0.864 | +39.8% | 11.98M | -23.9% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Nov 19, 2024 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Nov 19, 2024 | Jefferies | Upgrade | Hold | Buy |
| Nov 19, 2024 | BTIG | Upgrade | Neutral | Buy |
| Nov 18, 2024 | Piper Sandler | Upgrade | Neutral | Overweight |
| Sep 17, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Aug 19, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Jul 22, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Jan 22, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 11, 2024 | BTIG | Downgrade | Buy | Neutral |
| Dec 29, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 18, 2023 | Stifel | Maintained | Hold | Hold |
| Nov 14, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 14, 2023 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
| Nov 13, 2023 | Stifel | Downgrade | Buy | Hold |
| Nov 13, 2023 | William Blair | Downgrade | Outperform | Market Perform |
| Oct 9, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Oct 4, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 3, 2023 | Evercore ISI Group | Initiated | — | Outperform |
| Sep 19, 2023 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Sep 19, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 14, 2023 | Stifel | Maintained | Buy | Buy |
| Aug 8, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 14, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 7, 2023 | Goldman Sachs | Maintained | — | Buy |
| Mar 7, 2023 | BTIG | Maintained | — | Buy |
| Mar 7, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 24, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 7, 2023 | Cantor Fitzgerald | Reiterated | — | Overweight |
| Dec 14, 2022 | Stifel | Initiated | — | Buy |